These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38691662)

  • 1. Cognitive Outcomes in Nonacute Patients With Schizophrenia Treated With Long-Acting Injectable Antipsychotics Versus Oral Antipsychotics.
    Petric PS; Teodorescu A; Miron AA; Manea MC; Ifteni P
    Am J Ther; 2024 May-Jun 01; 31(3):e219-e228. PubMed ID: 38691662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge.
    Marcus SC; Zummo J; Pettit AR; Stoddard J; Doshi JA
    J Manag Care Spec Pharm; 2015 Sep; 21(9):754-68. PubMed ID: 26308223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LAI versus oral: A case-control study on subjective experience of antipsychotic maintenance treatment.
    Pietrini F; Spadafora M; Tatini L; Talamba GA; Andrisano C; Boncompagni G; Manetti M; Ricca V; Ballerini A
    Eur Psychiatry; 2016 Sep; 37():35-42. PubMed ID: 27442981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder.
    Greene M; Yan T; Chang E; Hartry A; Touya M; Broder MS
    J Med Econ; 2018 Feb; 21(2):127-134. PubMed ID: 28895758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment Patterns, Healthcare Resource Utilization and Costs Among Schizophrenia Patients Treated with Long-Acting Injectable Versus Oral Antipsychotics.
    Shah A; Xie L; Kariburyo F; Zhang Q; Gore M
    Adv Ther; 2018 Nov; 35(11):1994-2014. PubMed ID: 30269292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [French Society for Biological Psychiatry and Neuropsychopharmacology task force: Formal Consensus for the prescription of depot antipsychotics].
    Samalin L; Abbar M; Courtet P; Guillaume S; Lancrenon S; Llorca PM
    Encephale; 2013 Dec; 39 Suppl 4():189-203. PubMed ID: 24373464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world effectiveness of long-acting injectable vs. oral antipsychotics in patients with bipolar I disorder: a 1-year retrospective observational study.
    Korkmaz ŞA; Gürler S
    Curr Med Res Opin; 2024 May; 40(5):855-861. PubMed ID: 38557295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination Therapy of Long-Acting Injectable Second-Generation Antipsychotics and Oral Antipsychotics: A Retrospective Chart Review and Prescribers' Attitude Survey.
    Misawa F; Amemiya A; Fujii Y; Takeuchi H
    J Clin Psychopharmacol; 2022 Jan-Feb 01; 42(1):81-86. PubMed ID: 34668878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [LONG-ACTING INJECTABLE ANTIPSYCHOTICS IN SCHIZOPHRENIA].
    Teitelbaum A; Kodesh A
    Harefuah; 2019 Jul; 158(7):453-457. PubMed ID: 31339245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
    Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
    Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Long-Acting Injectable Antipsychotics With Oral Antipsychotics and Suicide and All-Cause Mortality in Patients With Newly Diagnosed Schizophrenia.
    Huang CY; Fang SC; Shao YJ
    JAMA Netw Open; 2021 May; 4(5):e218810. PubMed ID: 33974056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beneficial Effects of Concomitant Long-Acting Injectable Antipsychotics on Time to Rehospitalization in Patients With Treatment-Resistant Schizophrenia Receiving Clozapine: A Retrospective Cohort Study.
    Tien Y; Wang XY; Huang SC; Huang HP
    J Clin Psychiatry; 2024 May; 85(2):. PubMed ID: 38696112
    [No Abstract]   [Full Text] [Related]  

  • 13. Risk Factors, Incidence, and Outcomes of Neuroleptic Malignant Syndrome on Long-Acting Injectable vs Oral Antipsychotics in a Nationwide Schizophrenia Cohort.
    Guinart D; Taipale H; Rubio JM; Tanskanen A; Correll CU; Tiihonen J; Kane JM
    Schizophr Bull; 2021 Oct; 47(6):1621-1630. PubMed ID: 34013325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time to Treatment Discontinuation in German Patients with Schizophrenia: Long-Acting Injectables versus Oral Antipsychotics.
    Mahlich J; Olbrich K; Wilk A; Wimmer A; Wolff-Menzler C
    Clin Drug Investig; 2021 Jan; 41(1):99-113. PubMed ID: 33331979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment patterns in Medicaid patients with schizophrenia initiated on a first- or second-generation long-acting injectable versus oral antipsychotic.
    Pilon D; Joshi K; Tandon N; Lafeuille MH; Kamstra RL; Emond B; Lefebvre P
    Patient Prefer Adherence; 2017; 11():619-629. PubMed ID: 28356723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuation of schizophrenia treatment with three long-acting injectable antipsychotics in South Korea: A nationwide population-based study.
    Joo SW; Shon SH; Choi G; Koh M; Cho SW; Lee J
    Eur Neuropsychopharmacol; 2019 Sep; 29(9):1051-1060. PubMed ID: 31362852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baseline results from the European non-interventional Antipsychotic Long acTing injection in schizOphrenia (ALTO) study.
    Llorca PM; Bobes J; Fleischhacker WW; Heres S; Moore N; Bent-Ennakhil N; Sapin C; Loze JY; Nylander AG; Patel MX
    Eur Psychiatry; 2018 Aug; 52():85-94. PubMed ID: 29734130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three-Year Naturalistic Study On Early Use Of Long-Acting Injectable Antipsychotics In First Episode Psychosis.
    Medrano S; Abdel-Baki A; Stip E; Potvin S
    Psychopharmacol Bull; 2018 Jun; 48(4):25-61. PubMed ID: 30618474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies.
    Kishimoto T; Hagi K; Kurokawa S; Kane JM; Correll CU
    Lancet Psychiatry; 2021 May; 8(5):387-404. PubMed ID: 33862018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.